# Nostos Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nostos-genomics

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.nostos-genomics.com
- Total disclosed funding: $5.7M
- Latest round: Seed (Feb 3, 2022)
- Investors on record: 5

## About

Based in Berlin, Germany, and founded in 2018, Nostos Genomics GmbH operates as a healthcare technology firm that provides AI-based genetic analysis solutions. The company was founded by its CTO, Rocío Acuña Hidalgo, and CEO, David Gorgan. In February 2022, Nostos Genomics GmbH raised EUR 5 million in seed funding from 42CAP, Acequia Capital, Entrepreneur First, and Amino Collective. The seed funding values Nostos Genomics GmbH at EUR 11.86 post-money.

Nostos Genomics provides a genetic disease identification technology platform, which is an artificial intelligence-enabled genetic analysis platform that uses machine learning to detect genetic diseases. The company offers AION, a genetic variant interpretation platform that enables clinicians and researchers to submit case data, which includes a VCF file, family members, and patient characteristics, and then AION generates a report that includes the following information: a list of all variants that have been identified in the case, the classification of each variant (pathogenic, benign), and a list of diseases that are associated with each variant.

## Funding rounds

- Seed, Feb 3, 2022, $5.7M — Acequia Capital, Frontline, Entrepreneur First, 42Cap, Amino Collective

## Investors

- Acequia Capital (https://capitalatlas.ai/funds/acequia-capital) — Seed
- Frontline (https://capitalatlas.ai/funds/frontline) — Seed
- Entrepreneur First (https://capitalatlas.ai/funds/entrepreneur-first) — Seed
- 42Cap (https://capitalatlas.ai/funds/42cap) — Seed
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed